Tag: MRNA

  • CureVac is an Underappreciated Opportunity, Says UBS

    CureVac is an Underappreciated Opportunity, Says UBS

    Investors may want to keep an eye on CureVac (CVAC). After pulling back from about $12.50 to $10.50, CVAC could see higher highs.  In fact, according to a UBS analyst, the stock is ready to compete in the big leagues. “UBS analyst Eliana Merle upgraded the shares to Buy from Neutral and raised her 12-month…

  • The Top 3 Vaccine Trades that Should be in All Portfolios

    The Top 3 Vaccine Trades that Should be in All Portfolios

    Moderna (MRNA) has been incredibly explosive for us. The first time we highlighted opportunity, the stock traded at $72 on Oct. 20.  At the moment, it’s up to $171.92 in pre-market, and we still believe it could rally to $200. For one, “This positive primary analysis confirms the ability of our vaccine to prevent COVID-19…

  • This is Why Moderna Could Run to $200, Near-Term

    This is Why Moderna Could Run to $200, Near-Term

    Vaccine news has created big opportunity. Look at BioNTech for example.  The stock exploded from $88.50 to $124.24 after it and Pifzer said its vaccine had a 95% effective rate with no safety concerns. “Efficacy was consistent across age, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%,”Pfizer…

  • Moderna Inc. Could Have Vaccine by December 2020

    Moderna Inc. Could Have Vaccine by December 2020

    Keep an eye on Moderna Inc. (MRNA). The COVID-19 vaccine stock is regaining some lost ground.  All after CEO Stephane Bancel said the U.S. government could authorize emergency use of the company’s vaccine by December.  That is, if the company can produce positive interim results in November from its clinical trial. According to The Wall…